Glycopyrrolate and formoterol fumarate for the treatment of COPD.
Pierre-Edouard GrilletCosette Le SouderJuliette RohouOlivier CazorlaJérémy CharriotArnaud BourdinPublished in: Expert review of respiratory medicine (2020)
Within the fixed-dose combinations, Glycopyrrolate and formoterol fumarate offer a credible unique pMDI option to be given twice a day. LABA-LAMA offers an ICS-free alternative in COPD pharmacology which represents an important treatment option given the current debate over whether or not, maintenance triple therapy combined with ICS are benefic in the long term.